Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Atkins

Showing results (411-420 of 493) with videos related to

Pageof 50
Sort By:
CA: a Cancer Journal for Clinicians|June 16, 2004
An evidence-based staging system for cutaneous melanomaCharles M Balch, Seng-Jaw Soong, Michael B Atkins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2020
Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab <b>+</b> Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell CarcinomaMichael B Atkins, Brian I Rini, Robert J Motzer, et al.
Cancer Cell|November 6, 2020
Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis BlockadeRobert J Motzer, Romain Banchereau, Habib Hamidi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2017
Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced MelanomaMario Sznol, Pier Francesco Ferrucci, David Hogg, et al.
European Urology|July 17, 2022
Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell CarcinomaJens Bedke, Brian I Rini, Elizabeth R Plimack, et al.
Seminars in Surgical Oncology|August 19, 2003
New TNM melanoma staging system: linking biology and natural history to clinical outcomesCharles M Balch, Antonio C Buzaid, Seng-Jaw Soong, et al.
Gastroenterology|December 11, 2020
Cadherin 11 Promotes Immunosuppression and Extracellular Matrix Deposition to Support Growth of Pancreatic Tumors and Resistance to Gemcitabine in MiceIvana Peran, Sivanesan Dakshanamurthy, Matthew D McCoy, et al.
Cancer|March 16, 2000
A new American Joint Committee on Cancer staging system for cutaneous melanomaC M Balch, A C Buzaid, M B Atkins, et al.
Journal for Immunotherapy of Cancer|March 22, 2023
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 3, 2025
Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in CheckMate 204Raymond Y Huang, Gilbert Youssef, Thomas Nelson, et al.
Pageof 50

Showing results (411-420 of 493) with videos related to

Sort By:
Pageof 50
CA: a Cancer Journal for Clinicians|June 16, 2004
An evidence-based staging system for cutaneous melanomaCharles M Balch, Seng-Jaw Soong, Michael B Atkins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2020
Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab <b>+</b> Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell CarcinomaMichael B Atkins, Brian I Rini, Robert J Motzer, et al.
Cancer Cell|November 6, 2020
Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis BlockadeRobert J Motzer, Romain Banchereau, Habib Hamidi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2017
Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced MelanomaMario Sznol, Pier Francesco Ferrucci, David Hogg, et al.
European Urology|July 17, 2022
Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell CarcinomaJens Bedke, Brian I Rini, Elizabeth R Plimack, et al.
Seminars in Surgical Oncology|August 19, 2003
New TNM melanoma staging system: linking biology and natural history to clinical outcomesCharles M Balch, Antonio C Buzaid, Seng-Jaw Soong, et al.
Gastroenterology|December 11, 2020
Cadherin 11 Promotes Immunosuppression and Extracellular Matrix Deposition to Support Growth of Pancreatic Tumors and Resistance to Gemcitabine in MiceIvana Peran, Sivanesan Dakshanamurthy, Matthew D McCoy, et al.
Cancer|March 16, 2000
A new American Joint Committee on Cancer staging system for cutaneous melanomaC M Balch, A C Buzaid, M B Atkins, et al.
Journal for Immunotherapy of Cancer|March 22, 2023
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 3, 2025
Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in CheckMate 204Raymond Y Huang, Gilbert Youssef, Thomas Nelson, et al.
Pageof 50